Kedrion Biopharma’s Post

Invasive Group B Strep (#iGBS) in early infancy associated with higher risk of neurodevelopmental impairment in later life Children with a history of invasive Group B Streptococcus (#GBS) disease face a higher risk of moderate to severe neurodevelopmental impairment (#NDI) later in life compared to non-iGBS children, according to a new study published in The Lancet eClinicalMedicine. Risk of moderate/severe NDI among #iGBS survivors varied by location: 2.9% in India, 3.4% in Kenya, 7.7% in Mozambique, 13.9% in South Africa and 23.1% in Argentina. Frequency of mild neurodevelopmental impairment also varied between the countries included in the study, ranging from 18% in Mozambique to 61% in Argentina. The study highlights the need for freely available standardised developmental assessment tests that can be adapted to context for routine use in both clinical practice and to inform public health policy. Better #detection of #iGBS is also needed to link to better healthcare and education for affected children and comprehensive support for their families, requiring context-specific implementation research. https://lnkd.in/gBcaxUwm

🌟 We recently hosted the Biofire Connect events in Chennai and New Delhi, bringing together an incredible community of clinicians from various fields like Critical care, ID, pediatrics and microbiologists. These gatherings provided a unique platform for sharing experience, insights, and discussing the benefits and caveats of Syndromic multiplex PCR testing solution by BioFire, empowering everyone in the fight against infectious diseases. 🔬 Our expert speakers delivered impactful sessions on the latest advancements in rapid diagnostics, showcasing the power of Biofire in clinical settings. Specifically curated talks addressed key topics in infectious disease management, emphasizing the critical role of accurate and timely diagnostics. 💬 The interactive discussions left everyone inspired and equipped with new knowledge to enhance patient care. 🙏 A huge thank you to all the eminent speakers, participants and organizers for making these events a resounding success. Together, we're making strides in improving healthcare and tackling infectious diseases head-on. 📅 Stay tuned for more updates and upcoming events as we continue to connect and collaborate for a healthier future! #BiofireConnect #HealthcareInnovation #InfectiousDiseases #RapidDiagnostics #Collaboration #PatientCare #HealthcareCommunity #patientsafety

Today is International Neonatal Screening Day. Newborn screening is critical for the early detection of many genetic diseases, providing accurate diagnoses and ensuring rapid referrals within the first few weeks of life. For patients with Krabbe disease, newborn screening is essential. It significantly reduces the time to access vital treatments, which is crucial for their health outcomes. Thanks to the advocacy efforts of patient families and organizations, more states now include Krabbe disease on their newborn screening panels or have RUSP (recommended uniform screening panel) alignment legislation. Learn more about the importance of neonatal screening here ➡️ https://hubs.li/Q02DHcfM0

The 10-fold rise in congenital syphilis cases in the U.S. is surprising to many. However, this has been a global issue for many years. Winnie Fung and I published a study in the Journal of Health Economics in 2016 showing that state-mandated antenatal testing for syphilis, when first enacted, decreased neonatal mortality rates of nonwhites* by 8.6% and narrowed the white-nonwhite* neonatal mortality gap 18% by 1947. Unfortunately it appears that nearly 90% of cases in 2022 could have been prevented with timely testing and treatment. #healthpolicy JHE Publication can be found here: https://lnkd.in/eigzmXEA *Terms used in Vital Statistics data reports published 1931-1947.

🔔 Every year, more than 38,000 newborns benefit from a life-changing diagnosis enabled by neonatal screening, but over 100,000 newborns with rare diseases do not have access to any form of screening at birth. 🔊 As you can read more in the Screen4Rare press release: "The WHO’s provision on neonatal screening could be transformative for children around the world with treatable rare diseases. 🎙 For current and future generations neonatal screening is not merely a test; it can be a life-changing public health intervention that has the power to diagnose and treat disorders at their earliest stages. 🔬 Despite public health becoming a priority concern for many citizens, global access to this cost-effective intervention remains out of reach for many. Only one in three babies undergo any form of screening at birth. 💯 A simple heel-prick test, if universally implemented and accompanied by proper treatment, could help over 100,000 newborns annually and significantly improve their long-term outcome." 💡 Luckily, we have long-term practice of hashtag #newbornscreening in Serbia, and also one test which can screen the mutations for over 100 diseases. If you want to learn more, click the link here >>> https://lnkd.in/djcuhbH9 #genetictesting #premiumgenetics #newbornscreening #babyshealth

Press Alert: 📢 Newborn Screening Emergency: Urgent Call for Action to Identify 10,000+ Undiagnosed Rare Diseases "The way to accelerate rare diseases is clear and technologies are mature and available now in both the U.S., and India, but just not being tapped into due to lack of will or supporting public health policies. Fixing this now urgently can dramatically improve the whole equation for rare diseases by bringing millions of undiagnosed patients into the fold." Read Full Story: https://lnkd.in/eseWRdJM Annie Kennedy Indo US Organization for Rare Diseases (IndoUSrare) EveryLife Foundation for Rare Diseases Reena Kartha Nisha Venugopal Frank Sasinowski Anish Bhatnagar Juhi Naithani Narayanan Govindarajan Ramya T karur Lavanyaa Manjunatha, PhD Saundarya M S Deepti Dubey, PhD Dr. Kruti Varshney #AI #Newbornscreening #NBS #rarediseases #undiagnosed #patientidentification #earlydiagnosis

Today, June 28th, we are celebrating International Neonatal Screening Day. #INSD 🌍 Patient care and wellbeing is the ultimate goal of all European Blood Alliance members’ operations. Newborn screening identifies conditions in infants before symptoms appear and has been shown to decrease mortality and increase quality of life. By including Newborn Screening as an integral part of an EU rare diseases strategy, the EU could: - Reduce the inequities which arise from the existing heterogeneity in national approaches to screening and prevention of rare diseases - Facilitate more informed and transparent decision-making in national #PlasmaStrategies, the #CriticalMedicinesAlliance, and other initiatives aiming to ensure patients have stable and adequate access to the medicines they need - Enable the EU become the international example of achieving equity for the rare disease community. Measures designed to optimise the European neonatal screening environment will also better Europe’s position to work with other global regions on ensuring patients there also have their needs met. On this International Neonatal Screening Day, we add our voice to those advocating to raise Newborn Screening as a fundamental tool to access care. Screen4Rare IPOPI - International Patient Organisation for Primary Immunodeficiencies International Society for Neonatal Screening The European Society for Immunodeficiencies (ESID)

📃Scientific paper: COVID-19 pandemic effects on neonatal inpatient admissions and mortality: interrupted time series analysis of facilities implementing NEST360 in Kenya, Malawi, Nigeria, and Tanzania Abstract: Background The emergence of COVID-19 precipitated containment policies (e.g., lockdowns, school closures, etc.). These policies disrupted healthcare, potentially eroding gains for Sustainable Development Goals including for neonatal mortality. Our analysis aimed to evaluate indirect effects of COVID-19 containment policies on neonatal admissions and mortality in 67 neonatal units across Kenya, Malawi, Nigeria, and Tanzania between January 2019 and December 2021. Methods The Oxford Stringency Index was applied to quantify COVID-19 policy stringency over time for Kenya, Malawi, Nigeria, and Tanzania. Stringency increased markedly between March and April 2020 for these four countries (although less so in Tanzania), therefore defining the point of interruption. We used March as the primary interruption month, with April for sensitivity analysis. Additional sensitivity analysis excluded data for March and April 2020, modelled the index as a continuous exposure, and examined models for each country. To evaluate changes in neonatal admissions and mortality based on this interruption period, a mixed effects segmented regression was applied. The unit of analysis was the neonatal unit ( n  = 67), with a total of 266,741 neonatal admissions (January 2019 to December 2021). Results Admission to neonatal units decreased by 15% overall from February to March 2020, with half of the 67 neonatal units showing a decline in admissions. Of the 34 neonatal units with a decline in admi... Continued on ES/IODE ➡️ https://etcse.fr/TCMa ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Peadiatric Screening can prevent genetic diseases such as Familial Hypercholesterolaemia (FH) and improve immensely public health outcomes. #PERFECTO Preventing the Preventable, is an innovative #FH paediatric screening across Europe aiming to enable early diagnosis and management of this rare disease, with the hope that individuals with FH can reach normal life expectancy. #PERFECTO #FHScreening #PreventiveCare #GeneticScreening #SfRD #FH #CardiovascularDisease Referrals https://lnkd.in/eSBjhd8k

The long-term human and social costs of Group B Strep (#gbs) are even greater than had been previously understood. A major piece of research sheds light on the longer-term impacts of #gbs infection in the first days and months of a baby’s life. The study was conducted by a partnership of the London School of Hygiene and Tropical Medicine, U. of London, Aarhus University (Denmark), Amsterdam UMC (Netherlands) and the Dutch National Institute for Public Health and the Environment. It tracked nearly 25,000 children, born in Denmark and the Netherlands between 1997 and 2017. The results are published in the The Lancet Child & Adolescent Health. What this research demonstrates is the impact on the survivors of #gbs. The study found that later in life, 1 in 20 children who experienced #gbs have some form of neurodevelopmental disability. They are roughly twice as likely as other children to have neurodevelopmental impairments and to require special educational support. This means that the long-term human and social costs of #gbs are even greater than had been previously understood. https://lnkd.in/efENTBzJ #gbs #groupBstreptococcus  #healthcare #research #australia #pointofcare #devices #biotech #collaboration #project